Bill Text: NY S09726 | 2023-2024 | General Assembly | Introduced
Bill Title: Amends the definitions of diagnostic pharmaceuticals, topical therapeutic pharmaceutical agents, and therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension as they relate to the certification to use therapeutic drugs in the practice of optometry.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Introduced) 2024-05-23 - REFERRED TO HIGHER EDUCATION [S09726 Detail]
Download: New_York-2023-S09726-Introduced.html
STATE OF NEW YORK ________________________________________________________________________ 9726 IN SENATE May 23, 2024 ___________ Introduced by Sen. LIU -- read twice and ordered printed, and when printed to be committed to the Committee on Higher Education AN ACT to amend the education law, in relation to the use of topical pharmaceutical agents The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Paragraphs (d), (e) and (f) of subdivision 1 of section 2 7101-a of the education law, paragraph (d) as added by chapter 517 of 3 the laws of 1995 and paragraphs (e) and (f) as amended by chapter 506 of 4 the laws of 2021, are amended to read as follows: 5 (d) Diagnostic pharmaceuticals. Diagnostic pharmaceuticals shall mean 6 those drugs which shall be limited to topical applications [to the7surface of the eye] for the purpose of diagnostic examination of the eye 8 [and shall be limited to:9(i) Anesthetic agents;10(ii) Mydriatics;11(iii) Cycloplegics;12(iv) Miotics;13(v) Disclosing agents and other substances used in conjunction with14these drugs as part of a diagnostic procedure] and adnexa. 15 (e) Topical therapeutic pharmaceutical agents. Topical therapeutic 16 pharmaceutical agents shall mean those drugs which shall be limited to 17 topical application [to the surface of the eye] for therapeutic purposes 18 [and shall be limited to:19(i) antibiotic/antimicrobials;20(ii) decongestants/anti-allergenics;21(iii) non-steroidal anti-inflammatory agents;22(iv) steroidal anti-inflammatory agents;23(v) antiviral agents;24(vi) hyperosmotic/hypertonic agents;25(vii) cycloplegics;26(viii) artificial tears and lubricants; and27(ix) immunosuppressive agents] of the eye and adnexa. EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD14942-02-4S. 9726 2 1 (f) Therapeutic pharmaceutical agents for treatment of glaucoma and 2 ocular hypertension. Therapeutic pharmaceutical agents for treatment of 3 glaucoma and ocular hypertension shall mean those drugs which shall be 4 limited to topical application [to the surface] for therapeutic purposes 5 of the eye and [shall be limited to:6(i) beta blockers;7(ii) alpha agonists;8(iii) direct acting cholinergic agents;9(iv) prostaglandin analogs; and10(v) carbonic anhydrase inhibitors] adnexa. 11 § 2. Paragraph (e) of subdivision 4 of section 7101-a of the education 12 law, as added by chapter 517 of the laws of 1995 and as relettered by 13 chapter 506 of the laws of 2021, is amended to read as follows: 14 (e) The provisions of paragraphs (a) and (b) of this subdivision shall 15 not apply to (i) graduates of an appropriate program approved by the 16 department who have successfully passed the examination on the use of 17 diagnostic and therapeutic [drugs] agents and who graduated subsequent 18 to January first, nineteen hundred ninety-three; or (ii) optometrists 19 who have been certified for at least five years to use [phase one] 20 topical therapeutic agents and [phase two drugs] therapeutic pharmaceu- 21 tical agents for treatment of glaucoma and ocular hypertension in anoth- 22 er jurisdiction, have demonstrated such use in independently managed 23 patients, and have been licensed in accordance with section seventy-one 24 hundred four of this chapter. Provided, however, no optometrist exempt 25 under this paragraph shall be permitted to use [phase one] topical ther- 26 apeutic pharmaceutical agents or [phase two] therapeutic pharmaceutical 27 agents for treatment of glaucoma and ocular hypertension prior to the 28 general authorization provided to optometrists licensed in this state. 29 § 3. The opening paragraph of paragraph (b) and paragraph (c) of 30 subdivision 10 of section 7101-a of the education law, as amended by 31 chapter 506 of the laws of 2021, are amended to read as follows: 32 Those optometrists having been certified for topical therapeutic phar- 33 maceutical agents shall be authorized to use and prescribe all topical 34 therapeutic pharmaceutical agents [specified in paragraph (e) of subdi-35vision one of this section], which are FDA approved and commercially 36 available for topical use. 37 (c) Those optometrists having been certified for therapeutic pharma- 38 ceutical agents for treatment of glaucoma and ocular hypertension shall 39 be authorized to use and prescribe therapeutic pharmaceutical agents for 40 treatment of glaucoma and ocular hypertension [specified in paragraph41(f) of subdivision one of this section], which are FDA approved and 42 commercially available. 43 § 4. This act shall take effect immediately.